Literature DB >> 6289740

Pharmacokinetics of ketoconazole in patients with neoplastic diseases.

A W Maksymiuk, H B Levine, G P Bodey.   

Abstract

Twenty-seven patients with advanced malignancies were given 200 mg of ketoconazole orally every 6 or 12 h. Blood samples were collected during these intervals and after the last dose to determine plasma concentrations and half-lives. The mean plasma concentrations measured after the initial dose were 1.7 +/- 1.1 microgram/ml at 2 h, 0.9 +/- 0.2 microgram/ml at 6 h, and 0.7 +/- 0.4 microgram/ml at 8 h. Plasma concentrations rose significantly in patients on the every-6-h schedule. Concentrations were more variable in patients on the every-12-h schedule, and changes in mean plasma concentrations after 7 and 14 days were not significant. Half-lives ranged from 1.3 to 11.6 h in individual patients. The mean half-life for all patients studied was 3.7 +/- 0.6 h on day 1. The calculated area under the curve was 12.0 +/- 4.7 micrograms-h/ml on day 1; it increased after 7 and 14 days of administration (every-6-h schedule), suggesting plasma binding or wide drug distribution or both. Saturation of storage compartments is also suggested. Less than 1% of the administered dose was recoverable as active drug from the urine over 6 h.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6289740      PMCID: PMC183671          DOI: 10.1128/AAC.22.1.43

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  12 in total

1.  Unusual serum lipoprotein abnormality induced by the vehicle of miconazole.

Authors:  A G Bagnarello; L A Lewis; M C McHenry; A J Weinstein; H K Naito; A J McCullough; R J Lederman; T L Gavan
Journal:  N Engl J Med       Date:  1977-03-03       Impact factor: 91.245

2.  Miconazole therapy for treatment of fungal infections in cancer patients.

Authors:  W M Jordan; G P Bodey; V Rodriguez; S J Ketchel; J Henney
Journal:  Antimicrob Agents Chemother       Date:  1979-12       Impact factor: 5.191

3.  Therapy of disseminated or pulmonary coccidioidomycosis with ketoconazole.

Authors:  C Brass; J N Galgiani; S C Campbell; D A Stevens
Journal:  Rev Infect Dis       Date:  1980 Jul-Aug

4.  The activity of ketoconazole in mixed cultures of leukocytes and Candida albicans.

Authors:  M de Brabander; F Aerts; J van Cutsem; H van den Bossche; M Borgers
Journal:  Sabouraudia       Date:  1980-09

Review 5.  Miconazole in coccidiodomycosis. II. Therapeutic and pharmacologic studies in man.

Authors:  D A Stevens; H B Levine; S C Deresinski
Journal:  Am J Med       Date:  1976-02       Impact factor: 4.965

6.  In vitro activities of miconazole, miconazole nitrate, and ketoconazole alone and combined with rifampin against Candida spp. and Torulopsis glabrata recovered from cancer patients.

Authors:  M R Moody; V M Young; M J Morris; S C Schimpff
Journal:  Antimicrob Agents Chemother       Date:  1980-05       Impact factor: 5.191

7.  Cardiorespiratory toxicity due to miconazole.

Authors:  V Fainstein; G P Bodey
Journal:  Ann Intern Med       Date:  1980-09       Impact factor: 25.391

8.  Ketoconazole, an oral antifungal: laboratory and clinical assessment of imidazole drugs.

Authors:  D Borelli; J L Bran; J Fuentes; R Legendre; E Leiderman; H B Levine; A Restrepo; D A Stevens
Journal:  Postgrad Med J       Date:  1979-09       Impact factor: 2.401

9.  Fungal infections in the cancer patient.

Authors:  G P Bodey
Journal:  S Afr Med J       Date:  1977-12-10

10.  Oral therapy for experimental coccidioidomycosis with R41 400 (ketoconazole), a new imidazole.

Authors:  H B Levine; J M Cobb
Journal:  Am Rev Respir Dis       Date:  1978-10
View more
  11 in total

1.  The pharmacokinetics of ketoconazole after chronic administration in adults.

Authors:  N R Badcock; F D Bartholomeusz; D B Frewin; L N Sansom; J G Reid
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

2.  Influence of food on the pharmacokinetics of ketoconazole.

Authors:  T K Daneshmend; D W Warnock; M D Ene; E M Johnson; M R Potten; M D Richardson; P J Williamson
Journal:  Antimicrob Agents Chemother       Date:  1984-01       Impact factor: 5.191

3.  Systemic absorption of ketoconazole from vaginal pessaries.

Authors:  M D Ene; P J Williamson; T K Daneshmend; N R Blatchford
Journal:  Br J Clin Pharmacol       Date:  1984-02       Impact factor: 4.335

Review 4.  Clinical pharmacokinetics of systemic antifungal drugs.

Authors:  T K Daneshmend; D W Warnock
Journal:  Clin Pharmacokinet       Date:  1983 Jan-Feb       Impact factor: 6.447

5.  Ketoconazole. Infectious Diseases and Immunization Committee, Canadian Paediatric Society.

Authors: 
Journal:  CMAJ       Date:  1985-12-01       Impact factor: 8.262

Review 6.  New antifungal agents for the systemic mycoses.

Authors:  S M Ringel
Journal:  Mycopathologia       Date:  1990-02       Impact factor: 2.574

7.  Pharmacokinetics of ketoconazole and treatment evaluation in candidal infections.

Authors:  M Bardare; A M Tortorano; M C Pietrogrande; M A Viviani
Journal:  Arch Dis Child       Date:  1984-11       Impact factor: 3.791

8.  Serum fungistatic and fungicidal activity in volunteers receiving antifungal agents.

Authors:  F Meunier
Journal:  Eur J Clin Microbiol       Date:  1986-02       Impact factor: 3.267

Review 9.  Clinical pharmacokinetics of ketoconazole.

Authors:  T K Daneshmend; D W Warnock
Journal:  Clin Pharmacokinet       Date:  1988-01       Impact factor: 6.447

10.  Ketoconazole pharmacokinetics during chronic dosing in adults with haematological malignancy.

Authors:  R J Stockley; T K Daneshmend; M T Bredow; D W Warnock; M D Richardson; R R Slade
Journal:  Eur J Clin Microbiol       Date:  1986-10       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.